|
1）Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353: 2148
|
|
|
|
2）Takimoto E. Cyclic GMP signaling in cardiac myocytes. Circ J. 2012; 76: 1819-25
|
|
|
|
|
3）Lee DI, Zhu G, Sasaki T, et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015; 519: 472
|
|
|
|
|
|
4）Takimoto E, Champion HC, Belardi D, et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res. 2005; 96: 100
|
|
|
|
|
|
5）Zhang M, Takimoto E, Hsu S, et al. Myocardial remodeling is controlled by myocyte -targeted gene regulation of phosphodiesterase type 5. A controls nitric-oxide-independent cGMP and hypertrophic heart disease. J Am Coll Cardiol. 2010; 56: 2021-30
|
|
|
|
|
|
6）Pokreisz P, Vandenwijngaert S, Bito V, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009; 119: 408
|
|
|
|
|
|
7）Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005; 11: 214
|
|
|
|
|
|
8）Miller CL, Kai Y, Oikawa, et al. Cylic nucleotide phoshodiesterase 1A: a key regulator of cardiac fibroblast activation and extracelluar matrix remodeling in the heart. Basic Res Cardiol. 2011; 106: 1023-39
|
|
|
|
|
|
9）Sasaki H, Nagayama T, Blanton RM, et al. PDE5 inhibitor efficacy is estrogen dependent in female heart disease. J Clin Invest. 2014; 124: 2461-71
|
|
|
|
|
|
10）Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309: 1268
|
|
|
|
|
|
11）Riddle EL, Schwartzman RA, Bond M, et al. Multi-tasking RGS proteins in the heart: the next therapeutic target? Circ Res. 2005; 96: 401
|
|
|
|
|
|
12）Takimoto E, Koitabashi N, Hsu S, et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest. 2009; 119: 408
|
|
|
|
|
|
13）Tokudome T, Kishimoto I, Horio T, et al. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation. 2008; 117: 2329
|
|
|
|
|
|
14）Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011; 4: 8
|
|
|
|
|
|
15）Gheorghiade M, Greene SJ, Butler J, et al. Effect of Vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA. 2015; 314: 2251-62
|
|
|
|
|
|
16）McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993
|
|
|
|
|